Marginal zone lymphoma: Associated autoimmunity & auto-immune disorders

Similar documents
MALT LYMPHOMA. Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma

MALT LYMPHOMA. Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma

Splenic marginal zone NHL: Update on biology and therapy. Jonathan W. Friedberg M.D., M.M.Sc.

Pathology of the indolent B-cell lymphomas Elias Campo

PhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

Indolent Lymphomas: Current. Dr. Laurie Sehn

eastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Treatment Nodal Marginal Zone Lymphoma

History of autoimmune conditions and lymphoma prognosis

Autoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic

Diagnosis of lymphoid neoplasms has been

Learn more about diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of B-cell non-hodgkin s lymphoma 1

Primary thyroid lymphoma: The 40 year experience of a UK lymphoma treatment centre

What will we discuss today?

FOLLICULARITY in LYMPHOMA

Mimics of Lymphoma in Routine Biopsies. Mixed follicular and paracortical hyperplasia. Types of Lymphoid Hyperplasia

Inspiration for this talk. Introduction to Rituximab. Introduction to Rituximab (RTX) Introduction to Rituximab. Introduction to Rituximab

LYMPHOMAS an overview of some subtypes of NHLs

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

A c as e of MA LT ly m ph om a of the thy roid ac c om p any in g H as him ot o 's thy roiditis

Primary non-hodgkin Lymphomas of the Gastrointestinal Tract (GI-NHL)

SEQUENCING FOLLICULAR LYMPHOMA

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

original article S. Luminari 1 *, M. Cesaretti 1, L. Marcheselli 1, I. Rashid 2, S. Madrigali 1, A. Maiorana 3 & M. Federico 1 introduction

A CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey

BACKGROUND INFORMATION ON NON-HODGKIN S LYMPHOMA

Mimics of Lymphoma in Routine Biopsies. I have nothing to disclose regarding the information to be reported in this talk.

PRIMARY GASTRIC LYMPHOMA: CASE REPORT WITH REVIEW OF LITERATURE

Mucosa-associated lymphoid tissue lymphoma of the urinary bladder

The many faces of extranodal lymphoma

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Key words : low-grade MALT lymphoma, epithelial change, empty lamina propria, B-cell clonality, H. pylori, eradication, long-term follow-up

Lymphoma: What You Need to Know

Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)

Case Report Mucosa-Associated Lymphoid Tissue Lymphoma of the Lacrimal Gland: Sustained Remission after Eradication of Helicobacter Pylori Infection

Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results

Morphometric Characterization of Small Cell Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo

Bachelor of Chinese Medicine ( ) AUTOIMMUNE DISEASES

Spectrum of Malignant Lymphoma in a Tertiary Care Hospital of North Eastern India

A heterogeneous collection of diseases characterised by hypogammaglobulinemia.

Thyroiditis in the differential diagnosis of lymphoma

Conjunctival CD5+ MALT lymphoma and review of literatures

Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?

Clinicopathologic Profile and Outcome of Extranodal Diffuse Large B-Cell NHL: Egyptian National Cancer Institute Experience

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

Two Cases of Primary Gastric Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT)-type

Monsanto s Spin on its Roundup herbicide is Unwinding

Hemophagocytic Lymphohistiocytosis Secondary to T cell/histiocyte-rich Large B-cell Lymphoma

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307

Case Report Follicular lymphoma mimicking marginal zone lymphoma in lymph node: a case report

Non-Hodgkin s Lymphomas Version

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

Rituxan (rituximab) DRUG POLICY BENEFIT APPLICATION

Immunophenotypic Differentiation Between Neoplastic Plasma Cells in Mature B-Cell Lymphoma vs Plasma Cell Myeloma

Sally Barrington Martin Hutchings

JMSCR Vol. 03 Issue 06 Page June 2015

A rare clinical presentation of non Hodgkin Lymphoma as multiple neurofibromas with review of literature

A Case of Primary Mucosa-Associated Lymphoid Tissue Type Lymphoma of the Gallbladder

Michi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology

Autoimmunity and Principles of Transplantation Immunology

Introduction: The Revised (4 th Edition) World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues

Methotrexate-associated Lymphoproliferative Disorders

. Autoimmune disease. Dr. Baha,Hamdi.AL-Amiedi Ph.D.Microbiology

Mittal S et al. OncoExpert, 2016, Vol. 2(1): ISSN:

Immune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust

Neoplastic proliferation arising from white blood cells. Introductory remarks. Classification

Small B-cell (Histologically Low Grade) Lymphoma

Critical Analysis and Diagnostic Usefulness of Limited Immunophenotyping of B-Cell Non-Hodgkin Lymphomas by Flow Cytometry

Bendamustine for relapsed follicular lymphoma refractory to rituximab

Prognosis of Primary Thyroid Lymphoma: Demographic, Clinical, and Pathologic Predictors of Survival

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies

Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients

Case Report Autoimmune neutropenia preceding Helicobacter pylori-negative MALT lymphoma with nodal dissemination

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals

Lymphoma: The Basics. Dr. Douglas Stewart

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

How I treat High-risk follicular lymphoma

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307

Emerging targeted therapies for follicular lymphoma A future without chemotherapy

Low grade Non-Hodgkin Lymphoma: New Therapies & Updates

Low-grade B-cell lymphoma

See Important Reminder at the end of this policy for important regulatory and legal information.

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

During past decades, because of the lack of knowledge

3.1 Introduction. It is emphasised that not all tests are necessarily required in every case. 3.2 Taxonomic structure

Protocol for the Examination of Specimens From Patients With Hodgkin Lymphoma*

Immunohistochemical classification of haematolymphoid tumours. Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital

Contents. vii. Preface... Acknowledgments... v xiii

Zydelig. Zydelig (idelalisib) Description

4/7/13 SINUSITIS WHO ARE WE TREATING? AMANDA SAM CONLEY RN, MSN, CFN, LNC, FNP- BC

HEAD AND NECK LYMPHOMAS: A 20 YEAR RETROSPECTIVE REVIEW OF CASES DIAGNOSED IN AN ORAL PATHOLOGY UNIT, JOHANNESBURG, SOUTH AFRICA.

Ocular adnexal lymphoma comparison of MALT lymphoma with other histological types

The patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was:

Transcription:

Marginal zone lymphoma: Associated autoimmunity & auto-immune disorders Dr Andrew Wotherspoon Histopathology department Royal Marsden Hospital London, UK

AI disorders affect 5-9% of the world populagon >80 chronic illnesses B-cell NHL 10 th most common cancer world wide 3-4% of all malignancies Both seem to share the loss of regulatory checkpoints in the normal B-cell proliferagon

Epidemiological studies - AssociaGons between SS, SLE, HT, AIHA, ITP and NHL/MZL

Lymphomagenesis in the context of autoimmunity - Chronic inflammatory response & AG sgmulagon - Immunosurveillance deficiency - Resistance to apoptosis & deregulate lymphocyte reacgvity - Control of B-cell acgvagon - NF-kB: regulates survival and proliferagon in B cells; - BAFF (B-cell acgvagng factor): Lower levels lead to immunodeficiency, higher levels to immunological hyperacgvity/ autoimmunity; - Immunosupressive treatment

- 3 rd most common systemic AID - 9F:1M - Onset 40-60y Sjögren Syndrome (SS) - Chronic inflammagon of the exocrine glands - Acquired MALT - Epithelium destrucgon - RR6.6x to develop a lymphoma - RR30x to develop ENMZL of the salivary gland - Average interval between dx (SS-ENMZL): 7.5y

- Affects mostly women - Onset 45-65y - Chronic inflammagon - Acquired MALT - Atrophic thyroid follicles - Epithelium destrucgon Hashimoto s ThyroidiGs (HT) - ENMZL 25% of all primary thyroid lymphoma (PTL) - HT à PTL: 40-80x greater risk than in general populagon - HTàENMZL: 67x risk - HT-associated ENMZL is 3x more common in women (peak at 70y) - DiagnosGc interval HTàENMZL: 2-3 decades - HT pagents are also at a greater risk of developing MALT lymphomas in organs other than the thyroid

- Systemic AIDs Systemic lupus erythematosus (SLE) - Affects mostly women - Systemic chronic inflammagon - NHL risk is increased 2.7-4.1x - Average age at NHL dx: 50y - DiagnosGc interval SLEàNHL: 6.7-17.8y - 7.5RR to develop ENMZL (although DLBCL is the most common lymphoma subtype associated to SLE) - Role of immunosuppressant agents as a risk factor for NHL/ENMZL development is controversial.

Immune thrombocytopenic purpura (ITP) & Autoimmune haemolygc anaemia (AIHA) - These are frequent complicagons seen in the course of many NHL and AID - Both are seen in about 10-15% of pagents with SMZL and NMZL - Overlapping occurrences: paraneoplasgc syndrome? - More commonly occur synchronously with MZL diagnosis (Dasanu et al, 2015) - Other AIDs tend to precede MZL diagnosis

Prognosis - MZL: indolent behavior - Most pagents are diagnosed at an early stage (I/II) - Management may include a watch & wait approach - ENMZL: OS>80% at 5y* - NMZL: OS 55-75% at 5y* - For non localised lymphomas, high tumour burden or high grade transformagon: chemotherapy or chemoimmunotherapy *Isaacson P. Extra nodal marginal zone lymphoma: MALT lymphoma. In: Harris N, Jaffe E, Vardiman J, Campo E, Arber D, editors. Hematopathology. 1 st ed. Philadelphia, PA: Saunders Elsevier; 2011. p. 291e305. *Isaacson PCA, Nakamura S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid Gssue (MALT lymphoma). In: Campo E, Swerdlow S, Harris N, et al., editors. WHO classificagon of tumors of the hematopoiegc and lymphoid Gssues. 4th ed. Lyon, France: IARC; 2008. p.214e7.

Final comments - The most consistent associagons AID-ENMZL - SS - HT - SLE - ITP & AIHA - Chronic anggenic sgmulagon plays a key role in most MZL - AID are less frequently reported in SMZL and NMZL. - AID-related risk factors for lymphoma development are thought to be : - Older age at dx; - Long standing disease; - Severity of disease;